- Home
- HOG vs TNGX Comparison
HOG vs TNGX Comparison
Compare HOG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOG | TNGX |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | 6400 | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HOG | TNGX |
|---|---|---|
| Price | $23.23 | $25.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $24.00 | $20.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $4,473,175,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $8.22 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $17.09 | $1.04 |
| 52 Week High | $31.25 | $28.41 |
Technical Indicators
Market Signals| Indicator | HOG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 64.91 |
| Support Level | $22.75 | $6.54 |
| Resistance Level | $24.98 | N/A |
| Average True Range (ATR) | 0.82 | 1.62 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 62.44 | 69.08 |
Price Performance
Historical ComparisonAbout HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.